SLC5A2 and metabolic dysfunction-associated steatohepatitis: Based on these observations, we hypothesized that the combination of Pema with a drug that enhances the excretion of carbohydrates from the kidney via SGLT2 inhibition has the potential to improve TG accumulation and NASH development.